{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:42:17Z","timestamp":1787740937944,"version":"build-2784847793"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["2040-00060B"],"award-info":[{"award-number":["2040-00060B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lundbeck foundation Fellowship","award":["R345-2020-1977"],"award-info":[{"award-number":["R345-2020-1977"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-84547-1","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T21:49:26Z","timestamp":1736804966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pipeline for development of acylated peptide based CGRP receptor antagonist with extended half-life for migraine treatment"],"prefix":"10.1038","volume":"15","author":[{"given":"Jens Bjelke","family":"Kristensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbeth","family":"Elster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Lundh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Ballar\u00edn-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Alexopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kr\u00e6mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ditte Marie","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Leurs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Christian","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik H.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian A.","family":"Haanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda","family":"Degn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"issue":"3","key":"84547_CR1","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1042\/bj2690775","volume":"269","author":"M Zaidi","year":"1990","unstructured":"Zaidi, M. et al. Structure-activity relationship of human calcitonin-gene-related peptide. Biochem. J. 269(3), 775\u2013780 (1990).","journal-title":"Biochem. J."},{"issue":"4","key":"84547_CR2","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","volume":"94","author":"FA Russell","year":"2014","unstructured":"Russell, F. A. et al. Calcitonin gene-related peptide: Physiology and pathophysiology. Physiol. Rev. 94(4), 1099\u20131142 (2014).","journal-title":"Physiol. Rev."},{"issue":"1","key":"84547_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0306-4522(88)90018-8","volume":"25","author":"PK Mulderry","year":"1988","unstructured":"Mulderry, P. K. et al. Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience 25(1), 195\u2013205 (1988).","journal-title":"Neuroscience"},{"key":"84547_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/164_2018_201","volume":"255","author":"L Edvinsson","year":"2019","unstructured":"Edvinsson, L. Role of CGRP in migraine. Handb. Exp. Pharmacol. 255, 121\u2013130 (2019).","journal-title":"Handb. Exp. Pharmacol."},{"key":"84547_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/164_2018_130","volume":"255","author":"GS Cottrell","year":"2019","unstructured":"Cottrell, G. S. CGRP receptor signalling pathways. Handb. Exp. Pharmacol. 255, 37\u201364 (2019).","journal-title":"Handb. Exp. Pharmacol."},{"issue":"1","key":"84547_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12020-017-1404-4","volume":"58","author":"WG Lima","year":"2017","unstructured":"Lima, W. G. et al. Role of calcitonin gene-related peptide in energy metabolism. Endocrine 58(1), 3\u201313 (2017).","journal-title":"Endocrine"},{"issue":"1","key":"84547_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s10194-019-0979-y","volume":"20","author":"V Favoni","year":"2019","unstructured":"Favoni, V. et al. CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?. J. Headache Pain 20(1), 27 (2019).","journal-title":"J. Headache Pain"},{"issue":"4","key":"84547_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","volume":"158","author":"S Iyengar","year":"2017","unstructured":"Iyengar, S., Ossipov, M. H. & Johnson, K. W. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain 158(4), 543\u2013559 (2017).","journal-title":"Pain"},{"issue":"6","key":"84547_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40263-019-00630-6","volume":"33","author":"KA Haanes","year":"2019","unstructured":"Haanes, K. A. & Edvinsson, L. Pathophysiological mechanisms in migraine and the identification of new therapeutic targets. CNS Drugs 33(6), 525\u2013537 (2019).","journal-title":"CNS Drugs"},{"issue":"44","key":"84547_CR10","doi-asserted-by":"publisher","first-page":"10587","DOI":"10.1523\/JNEUROSCI.2211-17.2017","volume":"37","author":"A Melo-Carrillo","year":"2017","unstructured":"Melo-Carrillo, A. et al. Fremanezumab-A humanized monoclonal anti-CGRP antibody-inhibits thinly myelinated (Adelta) but not unmyelinated (C) meningeal nociceptors. J. Neurosci. 37(44), 10587\u201310596 (2017).","journal-title":"J. Neurosci."},{"key":"84547_CR11","doi-asserted-by":"publisher","first-page":"174480691983657","DOI":"10.1177\/1744806919836570","volume":"15","author":"L Zhang","year":"2019","unstructured":"Zhang, L. et al. Role of intraganglionic transmission in the trigeminovascular pathway. Mol. Pain 15, 1744806919836570 (2019).","journal-title":"Mol. Pain"},{"issue":"1","key":"84547_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1476-5381.2011.01633.x","volume":"166","author":"EL Moore","year":"2012","unstructured":"Moore, E. L. & Salvatore, C. A. Targeting a family B GPCR\/RAMP receptor complex: CGRP receptor antagonists and migraine. Br. J. Pharmacol. 166(1), 66\u201378 (2012).","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"84547_CR13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13543784.2019.1618830","volume":"28","author":"A Negro","year":"2019","unstructured":"Negro, A. & Martelletti, P. Gepants for the treatment of migraine. Expert Opin. Investig. Drugs 28(6), 555\u2013567 (2019).","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"7","key":"84547_CR14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/0333102419835459","volume":"39","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby, P. J. et al. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 39(7), 817\u2013826 (2019).","journal-title":"Cephalalgia"},{"issue":"1","key":"84547_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/jpet.115.227793","volume":"356","author":"L Shi","year":"2016","unstructured":"Shi, L. et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J. Pharmacol. Exp. Ther. 356(1), 223\u2013231 (2016).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"84547_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s10194-021-01351-2","volume":"22","author":"SJ Nahas","year":"2021","unstructured":"Nahas, S. J. et al. Efficacy and safety of fremanezumab in clinical trial participants aged >\/=60 years with episodic or chronic migraine: Pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies. J. Headache Pain 22(1), 141 (2021).","journal-title":"J. Headache Pain"},{"issue":"1","key":"84547_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby, P. J. & Edvinsson, L. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. 33(1), 48\u201356 (1993).","journal-title":"Ann. Neurol."},{"issue":"9","key":"84547_CR18","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1523\/JNEUROSCI.19-09-03423.1999","volume":"19","author":"PL Durham","year":"1999","unstructured":"Durham, P. L. & Russo, A. F. Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J. Neurosci. 19(9), 3423\u20133429 (1999).","journal-title":"J. Neurosci."},{"issue":"24","key":"84547_CR19","doi-asserted-by":"publisher","first-page":"7889","DOI":"10.1021\/jm8009298","volume":"51","author":"LP Miranda","year":"2008","unstructured":"Miranda, L. P. et al. Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J. Med. Chem. 51(24), 7889\u20137897 (2008).","journal-title":"J. Med. Chem."},{"issue":"4","key":"84547_CR20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/bip.22270","volume":"100","author":"LP Miranda","year":"2013","unstructured":"Miranda, L. P. et al. Peptide antagonists of the calcitonin gene-related peptide (CGRP) receptor with improved pharmacokinetics and pharmacodynamics. Biopolymers 100(4), 422\u2013430 (2013).","journal-title":"Biopolymers"},{"issue":"1","key":"84547_CR21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.xphs.2021.06.034","volume":"111","author":"K Srinivasan","year":"2022","unstructured":"Srinivasan, K. et al. Pharmacological, pharmacokinetic, pharmacodynamic and physicochemical characterization of FE 205030: A potent, fast acting, injectable CGRP receptor antagonist for the treatment of acute episodic migraine. J Pharm. Sci. 111(1), 247\u2013261 (2022).","journal-title":"J Pharm. Sci."},{"key":"84547_CR22","doi-asserted-by":"publisher","first-page":"832589","DOI":"10.3389\/fphar.2022.832589","volume":"13","author":"A Jamaluddin","year":"2022","unstructured":"Jamaluddin, A. et al. Lipidated calcitonin gene-related peptide (CGRP) peptide antagonists retain CGRP receptor activity and attenuate CGRP action in vivo. Front. Pharmacol. 13, 832589 (2022).","journal-title":"Front. Pharmacol."},{"issue":"12","key":"84547_CR23","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1093\/jpp\/rgad081","volume":"75","author":"PM Killoran","year":"2023","unstructured":"Killoran, P. M. et al. Novel peptide calcitonin gene-related peptide antagonists for migraine therapy. J. Pharm. Pharmacol. 75(12), 1581\u20131589 (2023).","journal-title":"J. Pharm. Pharmacol."},{"issue":"1","key":"84547_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","volume":"7","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Therapeutic peptides: Current applications and future directions. Signal Transduct. Target Ther. 7(1), 48 (2022).","journal-title":"Signal Transduct. Target Ther."},{"issue":"2 Pt 1","key":"84547_CR25","first-page":"E331","volume":"256","author":"T Chiba","year":"1989","unstructured":"Chiba, T. et al. Calcitonin gene-related peptide receptor antagonist human CGRP-(8\u201337). Am. J. Physiol. 256(2 Pt 1), E331\u2013E335 (1989).","journal-title":"Am. J. Physiol."},{"issue":"Pt 3","key":"84547_CR26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1042\/bj3120725","volume":"312","author":"P Kurtzhals","year":"1995","unstructured":"Kurtzhals, P. et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J. 312(Pt 3), 725\u201331 (1995).","journal-title":"Biochem. J."},{"issue":"18","key":"84547_CR27","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau, J. et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J. Med. Chem. 58(18), 7370\u20137380 (2015).","journal-title":"J. Med. Chem."},{"issue":"1","key":"84547_CR28","doi-asserted-by":"publisher","first-page":"21179","DOI":"10.1038\/s41598-021-00654-3","volume":"11","author":"S Ostergaard","year":"2021","unstructured":"Ostergaard, S. et al. The effect of fatty diacid acylation of human PYY(3\u201336) on Y(2) receptor potency and half-life in minipigs. Sci. Rep. 11(1), 21179 (2021).","journal-title":"Sci. Rep."},{"issue":"12","key":"84547_CR29","doi-asserted-by":"publisher","first-page":"5526","DOI":"10.1016\/j.bbagen.2013.04.023","volume":"1830","author":"D Sleep","year":"2013","unstructured":"Sleep, D., Cameron, J. & Evans, L. R. Albumin as a versatile platform for drug half-life extension. Biochim. Biophys. Acta 1830(12), 5526\u20135534 (2013).","journal-title":"Biochim. Biophys. Acta"},{"issue":"11","key":"84547_CR30","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.2174\/092986712799945003","volume":"19","author":"L Zhang","year":"2012","unstructured":"Zhang, L. & Bulaj, G. Converting peptides into drug leads by lipidation. Curr. Med. Chem. 19(11), 1602\u20131618 (2012).","journal-title":"Curr. Med. Chem."},{"issue":"8","key":"84547_CR31","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1007\/s11095-012-0739-z","volume":"29","author":"I Jonassen","year":"2012","unstructured":"Jonassen, I. et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm. Res. 29(8), 2104\u20132114 (2012).","journal-title":"Pharm. Res."},{"issue":"4","key":"84547_CR32","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/psc.1328","volume":"17","author":"A Santoprete","year":"2011","unstructured":"Santoprete, A. et al. DPP-IV-resistant, long-acting oxyntomodulin derivatives. J. Pept. Sci. 17(4), 270\u2013280 (2011).","journal-title":"J. Pept. Sci."},{"key":"84547_CR33","doi-asserted-by":"publisher","first-page":"11814","DOI":"10.1021\/acs.jmedchem.4c00417","volume":"67","author":"JC Nielsen","year":"2024","unstructured":"Nielsen, J. C. et al. Machine-learning-guided peptide drug discovery: Development of GLP-1 receptor agonists with improved drug properties. J. Med. Chem. 67, 11814\u201311826 (2024).","journal-title":"J. Med. Chem."},{"issue":"5","key":"84547_CR34","first-page":"894","volume":"41","author":"CS D'Santos","year":"1992","unstructured":"D\u2019Santos, C. S. et al. Stimulation of adenylate cyclase by amylin in CHO-K1 cells. Mol. Pharmacol. 41(5), 894\u2013899 (1992).","journal-title":"Mol. Pharmacol."},{"issue":"4 Suppl","key":"84547_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1476-5381.1997.tb06793.x","volume":"120","author":"O Arunlakshana","year":"1997","unstructured":"Arunlakshana, O. & Schild, H. O. Some quantitative uses of drug antagonists. 1958. Br. J. Pharmacol. 120(4 Suppl), 151\u201361 (1997).","journal-title":"Br. J. Pharmacol."},{"issue":"4 Suppl","key":"84547_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1476-5381.1997.tb06773.x","volume":"120","author":"HO Schild","year":"1997","unstructured":"Schild, H. O. pA, a new scale for the measurement of drug antagonism. 1947. Br. J. Pharmacol. 120(4 Suppl), 29\u201346 (1997).","journal-title":"Br. J. Pharmacol."},{"key":"84547_CR37","unstructured":"Lundberg, S.M.a.L., Su-In, A Unified Approach to Interpreting Model Predictions. (2017)."},{"issue":"6","key":"84547_CR38","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1359-6446(05)03370-2","volume":"10","author":"SR Hoare","year":"2005","unstructured":"Hoare, S. R. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov. Today 10(6), 417\u2013427 (2005).","journal-title":"Drug Discov. Today"},{"issue":"24","key":"84547_CR39","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.1021\/jm070861j","volume":"50","author":"K Madsen","year":"2007","unstructured":"Madsen, K. et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: Importance of fatty acid length, polarity, and bulkiness. J. Med. Chem. 50(24), 6126\u20136132 (2007).","journal-title":"J. Med. Chem."},{"issue":"17","key":"84547_CR40","doi-asserted-by":"publisher","first-page":"4128","DOI":"10.1021\/jm030630m","volume":"47","author":"LB Knudsen","year":"2004","unstructured":"Knudsen, L. B. Glucagon-like peptide-1: The basis of a new class of treatment for type 2 diabetes. J. Med. Chem. 47(17), 4128\u20134134 (2004).","journal-title":"J. Med. Chem."},{"issue":"3","key":"84547_CR41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1124\/jpet.121.000567","volume":"377","author":"MM Fletcher","year":"2021","unstructured":"Fletcher, M. M. et al. AM833 is a novel agonist of calcitonin family G protein-coupled receptors: Pharmacological comparison with six selective and nonselective agonists. J. Pharmacol. Exp. Ther. 377(3), 417\u2013440 (2021).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"22","key":"84547_CR42","doi-asserted-by":"publisher","first-page":"8523","DOI":"10.1073\/pnas.1203195109","volume":"109","author":"YG Kim","year":"2012","unstructured":"Kim, Y. G. et al. Peptidomics approach to elucidate the proteolytic regulation of bioactive peptides. Proc. Natl. Acad. Sci. U. S. A. 109(22), 8523\u20138527 (2012).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"84547_CR43","first-page":"1084","volume":"258","author":"M Mimeault","year":"1991","unstructured":"Mimeault, M. et al. Comparative affinities and antagonistic potencies of various human calcitonin gene-related peptide fragments on calcitonin gene-related peptide receptors in brain and periphery. J. Pharmacol. Exp. Ther. 258(3), 1084\u20131090 (1991).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"84547_CR44","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/sj.bjp.0704844","volume":"137","author":"DL Hay","year":"2002","unstructured":"Hay, D. L. et al. A comparison of the actions of BIBN4096BS and CGRP(8\u201337) on CGRP and adrenomedullin receptors expressed on SK-N-MC, L6, Col 29 and Rat 2 cells. Br. J. Pharmacol. 137(1), 80\u201386 (2002).","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"84547_CR45","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1021\/jm050613s","volume":"49","author":"M Lang","year":"2006","unstructured":"Lang, M. et al. Identification of the key residue of calcitonin gene related peptide (CGRP) 27\u201337 to obtain antagonists with picomolar affinity at the CGRP receptor. J. Med. Chem. 49(2), 616\u2013624 (2006).","journal-title":"J. Med. Chem."},{"issue":"7","key":"84547_CR46","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/bph.12072","volume":"170","author":"HA Watkins","year":"2013","unstructured":"Watkins, H. A. et al. Structure-activity relationships for alpha-calcitonin gene-related peptide. Br. J. Pharmacol. 170(7), 1308\u20131322 (2013).","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"84547_CR47","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1124\/mol.117.110916","volume":"93","author":"JM Booe","year":"2018","unstructured":"Booe, J. M. et al. Probing the mechanism of receptor activity-modifying protein modulation of GPCR ligand selectivity through rational design of potent adrenomedullin and calcitonin gene-related peptide antagonists. Mol. Pharmacol. 93(4), 355\u2013367 (2018).","journal-title":"Mol. Pharmacol."},{"issue":"9","key":"84547_CR48","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.str.2010.05.014","volume":"18","author":"E ter Haar","year":"2010","unstructured":"ter Haar, E. et al. Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. Structure 18(9), 1083\u20131093 (2010).","journal-title":"Structure"},{"issue":"7724","key":"84547_CR49","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41586-018-0535-y","volume":"561","author":"YL Liang","year":"2018","unstructured":"Liang, Y. L. et al. Cryo-EM structure of the active, G(s)-protein complexed, human CGRP receptor. Nature 561(7724), 492\u2013497 (2018).","journal-title":"Nature"},{"issue":"7","key":"84547_CR50","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1177\/24725552211019653","volume":"26","author":"SRJ Hoare","year":"2021","unstructured":"Hoare, S. R. J. The problems of applying classical pharmacology analysis to modern in vitro drug discovery assays: Slow binding kinetics and high target concentration. SLAS Discov. 26(7), 835\u2013850 (2021).","journal-title":"SLAS Discov."},{"issue":"6","key":"84547_CR51","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/j.1476-5381.2010.00863.x","volume":"161","author":"SJ Charlton","year":"2010","unstructured":"Charlton, S. J. & Vauquelin, G. Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays. Br. J. Pharmacol. 161(6), 1250\u20131265 (2010).","journal-title":"Br. J. Pharmacol."},{"issue":"14","key":"84547_CR52","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1177\/03331024211038884","volume":"41","author":"SL Christensen","year":"2021","unstructured":"Christensen, S. L. et al. CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine. Cephalalgia 41(14), 1413\u20131426 (2021).","journal-title":"Cephalalgia"},{"issue":"5","key":"84547_CR53","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1095\/biolreprod.104.031369","volume":"71","author":"PR Gangula","year":"2004","unstructured":"Gangula, P. R. et al. Mesenteric arterial relaxation to calcitonin gene-related peptide is increased during pregnancy and by sex steroid hormones. Biol. Reprod. 71(5), 1739\u20131745 (2004).","journal-title":"Biol. Reprod."},{"issue":"4","key":"84547_CR54","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/apha.12213","volume":"210","author":"L Edvinsson","year":"2014","unstructured":"Edvinsson, L. et al. Differential localization and characterization of functional calcitonin gene-related peptide receptors in human subcutaneous arteries. Acta Physiol. (Oxf.) 210(4), 811\u2013822 (2014).","journal-title":"Acta Physiol. (Oxf.)"},{"key":"84547_CR55","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.vph.2017.02.001","volume":"90","author":"M Sheykhzade","year":"2017","unstructured":"Sheykhzade, M. et al. Binding and functional pharmacological characteristics of gepant-type antagonists in rat brain and mesenteric arteries. Vascul. Pharmacol. 90, 36\u201343 (2017).","journal-title":"Vascul. Pharmacol."},{"issue":"8","key":"84547_CR56","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3390\/ph16081075","volume":"16","author":"T de Vries","year":"2023","unstructured":"de Vries, T. et al. Blocking the CGRP Receptor: Differences across Human Vascular Beds. Pharmaceuticals (Basel) 16(8), 1075 (2023).","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"84547_CR57","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1111\/j.1476-5381.2012.02129.x","volume":"167","author":"AJ McNeish","year":"2012","unstructured":"McNeish, A. J. et al. Endosomal proteolysis regulates calcitonin gene-related peptide responses in mesenteric arteries. Br. J. Pharmacol. 167(8), 1679\u20131690 (2012).","journal-title":"Br. J. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84547-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84547-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84547-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T22:41:41Z","timestamp":1736808101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84547-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84547"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84547-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.B.K., M.L., D.M.J. and H.H.H. owns stocks at Gubra. B.B.G., F.A., U.L., J.C.N., L.E. M.D., K.A.H. and M.K. declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1870"}}